drugset / Trial / NCT05348057

Clinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI

NCT05348057

Phase 4 Unknown 240 enrolled Qian geng
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aim to investigate the effect of ivabradine on reducing infarct size and improving left ventricular remodeling after in patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial enhanced MRI.

Timeline

Start
2021-08-01
Primary completion
2022-09-01
Completion
2022-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivabradine Small molecule 5 mg Oral